Regend Therapeutics
PrivateLast Round
Series C
Feb 11, 2026
Total Funding Raised
$67.68M
Company Overview
Regend Therapeutics is a biotechnology company that specializes in organ regeneration through progenitor cell-based regenerative medicine.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Regend Therapeutics Comparables
Compare Regend Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Audion Therapeutics | 78% | |
| Regeneron Pharmaceuticals | 68% | |
| Zehui Biotechnology | 65% |
Regend Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Feb 11, 2026 | ||||
| Series B | Mar 3, 2022 | ||||
| Angel | Aug 6, 2015 |
Regend Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| China Merchants Securities | Series B |
| Soochow Securities | Series B |
| Wanrong Hongtu | Series B |
| West Fountain Capital Management Limited | Series B |
| Hefei Hi-Tech VC | Series C |
| Hongtai Fund | Series C |
| Shenzhen Capital Group | Series B |
Recent news
Latest coverage and updates
- launchesSep 8, 2026
Regend Corp. launched REGEND001 lung regeneration therapy on Jan 1st '25.
- attends_eventAug 26, 2026
Regend Corp. attended event 2026 European Respiratory Society (ERS) International Congress on Sep 8th '26.
Regend Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Regend Therapeutics's valuation, stock price, and market status.
Is Regend Therapeutics a public or private company?
Regend Therapeutics is a private company.
What is the current stock price of Regend Therapeutics?
Regend Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Regend Therapeutics worth (valuation)?
Valuation information for Regend Therapeutics is not publicly available.
Can I buy Regend Therapeutics stock?
Regend Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Regend Therapeutics's last funding round?
Regend Therapeutics's most recent funding round was Series B on March 3, 2022.
Who are the main investors in Regend Therapeutics?
Key investors in Regend Therapeutics include Shenzhen Capital Group.
Will Regend Therapeutics IPO soon?
No public IPO plans have been announced for Regend Therapeutics.
How can I track Regend Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Regend Therapeutics's secondary market activity and sign up for updates.